Pengobatan Malaria Melalui Target Enzim
DOI:
https://doi.org/10.18196/mmjkk.v1i2.1905Keywords:
target obat, plasmodium falcifarum, prosses metabolisme purin, biosintesis pirimidin, protease, drug targets, Plasmodium falciparum, purine salvage pathway, pyrimidine biosynthesisAbstract
Plasmodium falciparum causes the most severe form of malaria which is fatal in many cases. The emergence of drug-resistant strains of P. falciparum to the standard therapy of malaria (i.e. kloroquin) requires the new drug en¬zyme targets to be identified. This review covers in details: the enzymes of purin salvage pathway; pyrimidine biosynthesis; protease involved in catabo¬lism on haemoglobin. The review also briefly touches upon other potential targets in the treatment of malaria falciparum.k
Plasmodium falciparum menyebabkan bentuk penyakit malaria yang paling berat yang menyebabkan kematian dalam banyak kasus. Munculnya strain-strain P. falciparum yang resisten obat antimalaria (yaitu klorokuin) mengharuskan untuk menggali target enzim obat baru yang dapat digunakan untuk pengobatan malaria. Tinjauan ini membicarakan secara detil tentang: enzim-enzim dalam proses metabolisme purin; biosintesis pirimidin dan protease yang terlibat dalam katabolisme hemoglobin. Selain itu, secara singkat tinjauan ini juga akan membicarakan tentang target enzim potensial lainnya untuk terapi malaria falciparum.
References
Bergmman PA., Human L, freese JA., 1991. Xanthine oxydase inhibits growth of Plasmodium falciparum in human erithrocytes in vitro. J. Clin. Invest. 88:1848-55.
Carlson J, Helmby H, Hill AV., Brewser D, Greenwood BM., Wahlgren M. 1990. Human cerebral malaria: association with erithrocyte rosseting and lack of anti-rosetting antibodies. Lancet. 336:1457-60.
Fry M, Pudney M. 1992. Site of action of the antimalarial hydroxunapthoquinone, 2-(tran-4-(4‘- chlorophenyl)cuclohexyl)-3-hydroxy-l, 4-napthoquinone (566C80). Biochem Parmacol. 43:1545-53
Gero AM., Brown GV., Sullivan WJ. 1984. Pyrimidine de novo synthesis during the life cycle of the intraerithrocytic stage of Plasmodium falciparum. J. Parasitol. 9:66-8.
Goldberg DE, Slater AF, Beavis R, Chait B, Cerami A, Haenderson GB. 1991. Hemoglobin degrada¬tion in human malaria phatogen Plasmodium falciparum: A catabolic pathway initiated by a specific aspartic protease. J. Exp. Med. 173:961-9.
Gluzman IY, Francis SE, Oksman A, Smith CE, Daffin KL, Goldberg DE. 1994. Order and the specificity of the Plasmodium falciparum haemoglobin degradation pathway. J. Clin. Invest. 93:1602-8.
Hammond D.J, Burchell J.R, Pudney M. 1985. Inhibition of Pyrimidine biosynthesis de novo in Plasmodium falciparum by 2-(4-t-butylcyclohexyl)-3-hydroxy-1,4-naphthoquinone in vitro. MolBiochem. Parasitol. 14:97-109
Hudson A.T. 1993. Atovaquon - A novel broad spectrum antiinfective drug. Parasitol Today, 9:66-8.
McKerrow JH, Sun E, Rosenthal PJ, Bouvier J. 1994. The protease and pathogenicyti of parasitic protozoa. Annu Rev. Microbiol. 47:821-53.
Reyes P, Rathod PK, Sanchez DJ, Mrema JE, Rieckmann KH, Heidrich HG. 1982. Enzymes of purine and pyrimidine metabolism from the human malaria parasite Plasmodium falciparum. Mol biochem Parasitol. 5:275-90.
Rosenthal PJ, Lee GK, Smith RE. 1993. Inhibition of Plasmodium vinckei cystein proteinase cures murine malaria. Jclin Invest. 91:1052-6.
Rosenthal PJ, Wollish WS, Palmer JT, Rasnick D. 1991. Antimalarial effects of peptides inhibitors of a Plasmodium falciparum cystein proteinase. J clin Invest. 88:1467-72.
Webster HK, Wiesmann WP, Pavia CS. 1984. Adenosine deaminase in malaria infection: effect of 2‘- deoxycoformycin in vivo. Adv. Exp Med biol. 165:225-9.
WHO, 2000. Malaria Control. WHO Plan of Action 2000-2001, World Health Organization Represen¬tative to Indonesia Internet.
WHO. 2001. Malaria in Indonesia: Prevention and Treatment. Internet. 1-5.
Downloads
Issue
Section
License
Copyright
Authors retain copyright and grant Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) the right of first publication with the work simultaneously licensed under an Attribution 4.0 International (CC BY 4.0) that allows others to remix, adapt and build upon the work with an acknowledgment of the work's authorship and of the initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
Authors are permitted to copy and redistribute the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK).
License
Articles published in the Mutiara Medika: Jurnal Kedokteran dan Kesehatan (MMJKK) are licensed under an Attribution 4.0 International (CC BY 4.0) license. You are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
This license is acceptable for Free Cultural Works. The licensor cannot revoke these freedoms as long as you follow the license terms. Under the following terms:
Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
